Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Morari

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Neurobiology of Disease|March 22, 2025
Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in miceDaniela Mercatelli, Alberto Brugnoli, Anna Di Maio, et al.
British Journal of Pharmacology|August 7, 2002
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitroAnna Siniscalchi, Donata Rodi, Michele Morari, et al.
Cell Death & Disease|February 14, 2018
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's diseaseAlessandro Tozzi, Michela Tantucci, Saverio Marchi, et al.
Peptides|March 24, 2010
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4)Mattia Volta, Matteo Marti, John McDonald, et al.
STAR Protocols|December 13, 2025
Protocol to count the number of noradrenergic neurons in mouse locus coeruleus by unbiased stereologyLetizia Zanetti, Maria Regoni, Elena Monzani, et al.
Neurobiology of Disease|August 22, 2021
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivoFederica Albanese, Daniela Mercatelli, Luca Finetti, et al.
The European Journal of Neuroscience|August 20, 2003
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's diseaseMatteo Marti, Flora Mela, Linda Ulazzi, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 24, 2017
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal GangliaMichele Morari, Alberto Brugnoli, Clarissa Anna Pisanò, et al.
Neuropharmacology|February 23, 2020
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's diseaseClarissa A Pisanò, Alberto Brugnoli, Salvatore Novello, et al.
British Journal of Pharmacology|May 29, 2020
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulataSergio Vegas-Suárez, Clarissa Anna Pisanò, Catalina Requejo, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Neurobiology of Disease|March 22, 2025
Enhancement of D1 dopaminergic responses in aged LRRK2 G2019S knock-in miceDaniela Mercatelli, Alberto Brugnoli, Anna Di Maio, et al.
British Journal of Pharmacology|August 7, 2002
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitroAnna Siniscalchi, Donata Rodi, Michele Morari, et al.
Cell Death & Disease|February 14, 2018
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's diseaseAlessandro Tozzi, Michela Tantucci, Saverio Marchi, et al.
Peptides|March 24, 2010
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4)Mattia Volta, Matteo Marti, John McDonald, et al.
STAR Protocols|December 13, 2025
Protocol to count the number of noradrenergic neurons in mouse locus coeruleus by unbiased stereologyLetizia Zanetti, Maria Regoni, Elena Monzani, et al.
Neurobiology of Disease|August 22, 2021
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivoFederica Albanese, Daniela Mercatelli, Luca Finetti, et al.
The European Journal of Neuroscience|August 20, 2003
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington's diseaseMatteo Marti, Flora Mela, Linda Ulazzi, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 24, 2017
Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal GangliaMichele Morari, Alberto Brugnoli, Clarissa Anna Pisanò, et al.
Neuropharmacology|February 23, 2020
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's diseaseClarissa A Pisanò, Alberto Brugnoli, Salvatore Novello, et al.
British Journal of Pharmacology|May 29, 2020
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulataSergio Vegas-Suárez, Clarissa Anna Pisanò, Catalina Requejo, et al.
Pageof 10